We read with interest the 1 June, 2007 article by Tsurushima et al. 1 reporting a novel strategy for the treatment of malignant gliomas that combined tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy and radiation therapy (RT). For this purpose, a plasmid pE4-TRAIL was constructed that included the radio-inducible early growth response gene 1 (Egr-1) promoter, and was tested using U251 and U87 glioma cells. The authors reported that the combination of pE4-TRAIL and RT exhibited synergistic cell death associated with upregulation of death receptors in cells with wild-type p53 expression.
TRAIL has been shown to selectively kill tumor cells by inducing the apoptosis-specific receptors, TRAIL-R1 and TRAIL-R2. 2 We have previously reported, in glioma cell lines, that the apoptosis in response to TRAIL may be unrelated to TRAIL-R2 expression but to the activation of the extrinsic (cleavage of caspase-8, caspase-3 and PARP) and mitochondrial apoptotic pathways. Furthermore, TRAIL treatment resulted in neutralization of the Akt pathway, which has been implicated in the resistance to TRAIL-induced apoptosis. 3 Taken together, our previous results and the recent study 1 indicate that the role of the upregulation of the TRAIL-R1 and TRAIL-R2 in the induction of apoptosis during TRAIL treatment is not clear yet. Nevertheless, we have constructed a recombinant replication-deficient adenovirus vector carrying the TRAIL-R2 cDNA, which may be able to answer these questions. It would be interesting to see if the overexpression of TRAIL-R2 induced by this adenovirus has an additional effect to the combination of pE4-TRAIL and RT in glioma cells, independently on the p53 status.
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